EGFR and osteoporosis: Mice with knockdown of EGFR activity in progenitors and osteoblasts, or treated with an EGFR-specific inhibitor, experience delayed formation of the secondary ossification center and recruitment of osteoblasts and osteoclasts, leading to osteoporosis 23, 24.